Morphine improved the antitumor effects on MCF-7 cells in combination with 5-Fluorouracil

Biomedicine and Pharmacotherapy

Volumn 68, Issue 3, 2014, Pages 299-305

  Ge, Zhi Hua ^a   Wang, Zhi Xue ^a   Yu, Tie Li ^a   Yang, Ning ^a   Sun, Yu ^a   Hao, Chang Lai ^a   Sun, Li Xin ^a  

^a CHENGDE MEDICAL COLLEGE   (China)

Author keywords

5 Fluorouracil; Apoptosis; Bax; Bcl 2; Morphine; Tumor

Indexed keywords

FLUOROURACIL; LIPOCORTIN 5; MORPHINE; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC ANTIMETABOLITE; NARCOTIC ANALGESIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PAIN; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; MALE;

ANALGESICS, OPIOID; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL PROLIFERATION; DRUG SYNERGISM; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MCF-7 CELLS; MORPHINE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84899489171     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.09.006     Document Type: Article

References (32)

1. Tay W., Ho K.Y. The role of interventional therapies in cancer pain management. Ann Acad Med Singapore 2009, 38:989-997.
2. Paice J.A., Ferrell B. The management of cancer pain. Ca Cancer J Clin 2011, 61:157-182.
3. Mercadante S., Fulfaro F. World health organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005, 16(Suppl.4):Iv132-Iv135.
4. Ventafridda V., Tamburini M., Caraceni A., De Conno F., Naldi F. A validation study of the who method for cancer pain relief. Cancer 1987, 59:850-856.
5. Expert working group of the European association for palliative care Morphine in cancer pain: modes of administration. BMJ 1996, 312:823-826.
6. Zech D.F., Grond S., Lynch J., Hertel D., Lehmann K.A. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain 1995, 63:65-76.
7. Showalter S.L., Showalter T.N., Witkiewicz A., Havens R., Kennedy E.P., Hucl T., et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?. Cancer Biol Ther 2008, 7:986-994.
8. Heidelberger C., Chaudhuri N.K., Danneberg P., Mooren D., Griesbach L., Duschinsky R., et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179:663-666.
9. Heidelberger C., Danenberg P.V., Moran R.G. Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol 1983, 54:58-119.
10. Wyatt M.D. WDM participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009, 66:788-799.
11. Yu D.F., Wu F.R., Liu Y., Liu H., Xia Q. Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. Biomed Pharmacother 2013, [Epub ahead of print]. 10.1016/j.biopha.2013.03.007.
12. Qian L., Xiang D., Zhang J., Zhu S., Gao J., Wang X., et al. Recombinant human interleukin-1 receptor antagonist reduces acute lethal toxicity and protects hematopoiesis from chemotoxicity in vivo. Biomed Pharmacother 2013, 67:108-115.
13. Ortiz R., Prados J., Melguizo C., Rama A.R., Alvarez P.J., Rodríguez-Serrano F., et al. Gef gene therapy enhances the therapeutic efficacy of cytotoxics in colon cancer cells. Biomed Pharmacother 2012, 66:563-567.
14. Yang S., Liu J., Chen Y., Jiang J. Reversal effect of Tween-20 on multidrug resistance in tumor cells in vitro. Biomed Pharmacother 2012, 66:187-194.
15. Yang L., Zhou X., Yang J., Yin X., Han L., Zhao D. Aspirin inhibits cytotoxicity of prion peptide PrP106-126 to neuronal cells associated with microglia activation in vitro. J Neuroimmunol 2008, 199:10-17.
16. Martins D.S.S.J., Bayne R.A., Cambray N., Hartley P.S., McNeilly A.S., Anderson R.A. Expression of activin subunits and receptors in the developing human ovary: activin A promotes germ cell survival and proliferation before primordial follicle formation. Dev Biol 2004, 266:334-345.
17. Afsharimani B., Cabot P.J., Parat M.O. Morphine use in cancer surgery. Front Pharmacol 2011, 2:46.
18. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park) 1998, 12:19-22.
19. Longley D.B., Harkin D.P., Johnston P.G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
20. Pettigrew C.A., Cotter T.G. Deregulation of cell death (apoptosis): implications for tumor development. Discov Med 2009, 8:61-63.
21. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 2008, 19:325-331.
22. Parsons M.J., Green D.R. Mitochondria in cell death. Essays Biochem 2010, 47:99-114.
23. Russo M., Mupo A., Spagnuolo C., Russo G.L. Exploring death receptor pathways as selective targets in cancer therapy. Biochem Pharmacol 2010, 80:674-682.
24. Azmi A.S., Wang Z., Philip P.A., Mohammad R.M., Sarkar F.H. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011, 16:59-70.
25. Chao D.T., Linette G.P., Boise L.H., White L.S., Thompson C.B., Korsmeyer S.J. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995, 182:821-828.
26. Chao D.T., Korsmeyer S.J. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998, 16:395-419.
27. Piche A., Grim J., Rancourt C., Gomez-Navarro J., Reed J.C., Curiel D.T. Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res 1998, 58:2134-2140.
28. Kyprianou N., King E.D., Bradbury D., Rhee J.G. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 1997, 70:341-348.
29. Johnson M.I., Robinson M.C., Marsh C., Robson C.N., Neal D.E., Hamdy F.C. Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate 1998, 37:223-229.
30. Gleave M.E., Miayake H., Goldie J., Nelson C., Tolcher A. Targeting Bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense Bcl-2 oligodeoxynucleotides. Urology 1999, 54:36-46.
31. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
32. Rajendran R.R., Kao G.D. "No Turning Bax" in the combined battle against prostate cancer. Clin Cancer Res 2007, 13:3435-3438.